A Biodefense Boondoggle

As pharmaceutical companies line up for multimillion-dollar contracts to make bioterrorism vaccines, some question whether the industry is up to the job.

Image: AP/Wide World Photos

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


On October 17, 2001, almost two weeks after Robert Stevens died of pulmonary anthrax at a hospital in West Palm Beach, Florida, the Bush administration unveiled its plans to build up, in a big way, the National Pharmaceutical Stockpile—the drugs, vaccines, chemical antidotes, antitoxins, and other medical supplies that are kept at the ready to respond to large-scale bioterrorist attacks. The White House asked Congress for more than $1.1 billion in emergency funds to expand the two-year-old program, and some lawmakers were soon talking of increasing that amount to as much as $10 billion. Little wonder that many of the nation’s pharmaceutical companies, aided by their Washington lobbyists, have been angling for seats aboard what one industry critic calls “another gravy train to cash in on some big government contracts.”

But the pedal-to-the-metal push to stockpile vaccines has left some lawmakers and public-health advocates questioning whether Washington may be throwing good money after bad. Exhibit A in the debate has been BioPort Corporation, the nation’s sole manufacturer of anthrax vaccine. Since 1998 the Defense Department has pumped more than $130 million into BioPort, a small, privately held company in Lansing, Michigan, in hopes of stockpiling enough vaccine to protect all 2.4 million U.S. soldiers and reservists against anthrax. The Pentagon has continued paying BioPort even though the company repeatedly failed Food and Drug Administration inspections and, as a result, was prohibited from shipping any vaccine.

One reason for the Pentagon’s reluctance to cut BioPort loose may be the company’s most prominent shareholder, retired Admiral William J. Crowe, who served as chairman of the Joint Chiefs of Staff in the Reagan and Bush administrations. Crowe received a 12.5 percent stake in the company, according to his spokesman, for lending his name and expertise. BioPort’s CEO, Fuad El-Hibri, is a German-born businessman who has founded and operated a dizzying array of companies, including a Panama-based franchise operation called BurgerLand International. Last year El-Hibri and his wife each made $1,000 contributions to George Bush’s presidential campaign, a gesture that was matched on the same day by three other BioPort executives. El-Hibri did not return calls for this article.

Late last year, Defense Secretary Donald Rumsfeld said the Pentagon was trying to help BioPort stay in business, but added that the contract “may not be savable.” The department is now banking on a 10-year, $343-million contract with DynPort, a joint venture of defense contractor DynCorp and Britain’s Porton International Ltd., to procure a variety of new vaccines for diseases including anthrax and smallpox.

On the civilian side, the vaccine stockpiling effort is overseen by the Department of Health and Human Services, which contracts with pharmaceutical companies. Industry officials have said they will need substantial subsidies to develop and produce vaccines. The first case of sticker shock for the department came in October, when several large drug companies submitted bids to make smallpox vaccine, with price tags up to four times higher than what the department had estimated.

Some critics warn that the industry simply may not be able to fulfill national security needs. In recent years, manufacturing problems at some companies and unexpected withdrawals from the market by others have led to shortages of vaccines for influenza, tetanus, pneumonia, and childhood meningitis. In November, a federal antiterrorism commission headed by Governor James Gilmore of Virginia called for the creation of a government-owned facility to develop and produce vaccines for certain dangerous diseases. “The private sector is unlikely to be the answer to some of the more difficult vaccine issues,” the commission said in its report. Just days later, citing “the inability of the private sector to meet the country’s needs for vaccines,” the National Academy of Sciences’ Institute of Medicine renewed its call for the creation of a federal agency to oversee the vaccine supply.

In the wake of last fall’s anthrax attacks, such proposals have been gaining support on Capitol Hill. “The idea of saying, ‘Let’s contract with a private firm and let them do it,’ that’s misguided,” Senator Tim Hutchinson (R-Ark.) said during a Senate hearing on bioterrorism in October. “There are certain things only government can do, and, in this case, the private sector has failed us terribly.”

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate